Merck & Co Inc at Evercore HealthCONx Conference Transcript
Okay. Well, thank you all for being here. Pleasure to have Merck management join us. Mike, pleasure to have you. Peter, pleasure to have you guys join. Before we get going, perhaps turning it over to you guys just to kick things off, what's on top of your minds, the biggest priorities, and we'll jump right into it.
Questions & Answers
Great. Yes. Well, thank you very much, Umer. Thanks to the team for having us today. 2019 has been a good year for us, right? I think we have the business performing well on multiple fronts. Clearly, we continue to experience success with our oncology portfolio, led by KEYTRUDA, which the momentum continues to grow strong.
We've obviously seen a huge opportunity. We've been able to capitalize on the huge opportunity among cancer where in the United States today, about 8 out of every 10 patients in this indication are now
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
